RET fusions were found in 10–20% of papillary thyroid cancers and 1–2% of NSCLC, while RET point mutations occur in approximately 60–90% of advanced medullary thyroid cancers (MTC) [123]. The gene discussed is RET; the disease is thyroid gland papillary carcinoma.